Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T15:01:40.026Z.
Calculation as of: 2026-10-06T15:01:40.026Z.
Quote observation: 2026-10-06T14:59:40.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: fe921af54d6420969180622b7fbdd7ef934f73e64ffcc47ddb287d73eacb5931
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$11.21M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$11.24M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$11.30M
Price/FCF Ratio
N/A
TTM Avg
6.98
3Y Avg
6.98
5Y Avg
6.98
Market Cap
$10.93M
Price/FCF Ratio
N/A
TTM Avg
5.33
3Y Avg
5.33
5Y Avg
5.33
Market Cap
$11.68M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BioVie Inc. (BIVI) | $11.12M | N/A | N/A | N/A | N/A |
| Biofrontera Inc. (BFRI)vs › | $11.19M | N/A | N/A | N/A | N/A |
| Adial Pharmaceuticals, Inc. (ADIL)vs › | $11.21M | N/A | N/A | N/A | N/A |
| CytoMed Therapeutics Limited (GDTC)vs › | $11.24M | N/A | N/A | N/A | N/A |
| Kiora Pharmaceuticals, Inc. (KPRX)vs › | $11.30M | N/A | 6.98 | 6.98 | 6.98 |
| Lisata Therapeutics, Inc. (LSTA)vs › | $10.93M | N/A | 5.33 | 5.33 | 5.33 |
| Cerenome, Inc. (CNSY)vs › | $10.88M | N/A | N/A | N/A | N/A |
| Bullfrog AI Holdings, Inc. Common Stock (BFRG)vs › | $11.68M | N/A | N/A | N/A | N/A |
| Lifeward Ltd. (LFWD)vs › | $10.47M | N/A | N/A | N/A | N/A |
| Satellos Bioscience Inc. (MSLE)vs › | $10.45M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
